Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A higher occurrence of 1q gain and MYCN gain and a lack of difference in the distribution of variations among survivors and those with a relapse suggest a different molecular profile of Wilms tumor in Indian children.
|
31851072 |
2019 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between MYCN gene polymorphisms and Wilms tumor susceptibility.
|
31343784 |
2019 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By selecting focal regions commonly involved in chromosomal anomalies, we identified genes with a possible role in WT development, based on the prior knowledge of their biological relevance, including <i>MYCN, DIS3L2, MIR562</i>, <i>HACE1</i>, <i>GLI3</i>, <i>CDKN2A</i> and <i>CDKN2B</i>, <i>PALB2</i>, and <i>CHEK2</i>.
|
30344923 |
2018 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
|
28825729 |
2017 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest a significant role for MYCN dysregulation in the molecular biology of Wilms tumour.
|
25749049 |
2015 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We supposed that germline DDX1-MYCN duplication could also be involved in the apparition of nephroblastomas.
|
24161495 |
2013 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
|
21882282 |
2011 |
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reduced RA pathway activity and MYCN overexpression were found in high risk tumors as opposed to tumors with low/intermediate risk, suggesting a beneficial impact of RA especially on advanced WT.
|
22067876 |
2011 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the WT1 gene, located at 11p13, has been proven to be implicated in the development of Wilms tumor, other genes such as MYCN are also involved.
|
20186010 |
2010 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging therapies that target MYCN, which is amplified in several other pediatric cancers, may therefore be of value in high risk Wilms' tumor.
|
20332316 |
2010 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, our findings suggest that WT is an additional childhood tumor where MYCN gain might play an important role in tumor development.
|
17175381 |
2007 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This suggests that the repression of the N-myc promoter is mediated through the WT1 binding sites.
|
10470095 |
1999 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA, extracted from tumours arising in 29 paediatric patients [14 neuroblastoma, 9 Wilms tumour (nephroblastoma), 6 miscellaneous] was investigated for evidence of N-myc amplification, using pNb-1, a recombinant plasmid containing a 1.0 Kb fragment homologous to the 5' end of the human N-myc gene.
|
2172180 |
1990 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Similarly, the human N-myc gene was transcribed at an equivalent rate in HeLa cells, which do not accumulate this RNA in the cytoplasm, and cell lines G401 (a Wilms tumor-derived cell line) and SKNMc (established from a primitive neuroepithelioma), which do express N-myc RNA.
|
2147226 |
1990 |